Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Historically cutaneous and peripheral T-cell lymphomas have response rates of approximately
30% to standard chemotherapy regimens. We alternatively hypothesize that MLN9708 will be
active in this disease and will improve best objective response.
We will also determine the extent to which MLN9708 inhibits GATA-3 (Trans-acting
T-cell-specific transcription factor) expression, which is associated with poor prognosis,
and whether GATA-3 expression represents a novel predictive biomarker for MLN9708
sensitivity.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center